Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiliximab plus FCR versus FCR alone in relapsed chronic lymphocytic leukemia
2006-002987-24Phase 2Completed
- Sponsor
- Biogen
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lumiliximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Biogen. Primary endpoint: Investigator-determined complete response rate without the use of CT scans. Started Oct 2006; status: completed.
02
Drugs
lumiliximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-002987-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002987-24.